ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY

Clinical trials for ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY explained in plain language.

Never miss a new study

Get alerted when new ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY trials appear

Sign up with your email to follow new studies for ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental drug hopes to slow rare muscle disease in two patients

Disease control ENROLLING_BY_INVITATION

This early-stage trial tests a daily injection of ASA-001 in two adults with a rare genetic muscle disease (ADSS1 deficient myopathy). The main goals are to see if the drug is safe and if it can slow the disease. Participants will take the drug for 8 months and have clinic visits…

Matched conditions: ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY

Phase: PHASE1 • Sponsor: Cure ADSSL1 • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY

Get alerted when new ADENYLOSUCCINATE SYNTHASE 1 DEFICIENT MYOPATHY trials appear

Experimental drug hopes to slow rare muscle disease in two patients